Wow! Pulling out a 69 year old article!
Both old and new reasons for why Amarin should have chosen a different placebo oil. Clear to me even w/o that old article that mineral oil was a horrible placebo choice. Despite this placebo issue, Vascepa clearly reduced 5- and 3- point MACE and other secondary endpoints in REDUCE-IT. Successful CVOT. Placebo issue complicates but doesn't compromise the REDUCE-IT trial.
BearDownAZ
